Abstract
Currently, there are limited national data on the dose-dependent effect and long-term results of glucocorticosteroid (GCS) therapy in severe attacks of ulcerative colitis (UC). Approximately 20% of UC patients have chronic active disease, which requires the appointment of several courses of systemic GCS to achieve remission but with a decrease in the dose of corticosteroids or soon after their cancellation, a relapse of UC occurs. The determination of the optimal duration of therapy and dosing of GCS remains an unresolved and controversial scientific problem to achieve disease remission and prevention of steroid dependence and steroid resistance while minimizing the side effects of steroid therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
